Terms: = Thyroid cancer AND PAX8, ENSG00000125618, 7849 AND Prognosis
51 results:
1. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
2. [Clinicopathological features of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma].
Zhu M; Li J; Zheng WH; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2023 Aug; 52(8):820-826. PubMed ID: 37527987
[No Abstract] [Full Text] [Related]
3. Papillary thyroid carcinoma with aggressive fused follicular and solid growth pattern: A unique histological subtype with high-grade malignancy?
Murata SI; Matsuzaki I; Kishimoto M; Katsuki N; Onishi T; Hirokawa M; Kojima F
Pathol Int; 2023 May; 73(5):207-211. PubMed ID: 37042564
[TBL] [Abstract] [Full Text] [Related]
4. Immunohistochemical characteristics of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: A case report and review.
Guo H; Zhang Z; Huang C; Qiu J; Qu X
Medicine (Baltimore); 2023 Jan; 102(4):e32655. PubMed ID: 36705380
[TBL] [Abstract] [Full Text] [Related]
5. Papillary thyroid Carcinoma With Squamous Dedifferentiation: A Potential Diagnostic Pitfall.
Ijaz K; Yin F
Anticancer Res; 2023 Jan; 43(1):255-258. PubMed ID: 36585182
[TBL] [Abstract] [Full Text] [Related]
6. NUTM1 -rearranged Carcinoma of the thyroid : A Distinct Subset of NUT Carcinoma Characterized by Frequent NSD3 - NUTM1 Fusions.
Barletta JA; Gilday SD; Afkhami M; Bell D; Bocklage T; Boisselier P; Chau NG; Cipriani NA; Costes-Martineau V; Ghossein RA; Hertzler HJ; Kramer AM; Limaye S; Lopez CA; Ng TL; Weissferdt A; Xu B; Zhang S; French CA
Am J Surg Pathol; 2022 Dec; 46(12):1706-1715. PubMed ID: 36040068
[TBL] [Abstract] [Full Text] [Related]
7. pax8 and MECOM are interaction partners driving ovarian cancer.
Bleu M; Mermet-Meillon F; Apfel V; Barys L; Holzer L; Bachmann Salvy M; Lopes R; Amorim Monteiro Barbosa I; Delmas C; Hinniger A; Chau S; Kaufmann M; Haenni S; Berneiser K; Wahle M; Moravec I; Vissières A; Poetsch T; Ahrné E; Carte N; Voshol J; Bechter E; Hamon J; Meyerhofer M; Erdmann D; Fischer M; Stachyra T; Freuler F; Gutmann S; Fernández C; Schmelzle T; Naumann U; Roma G; Lawrenson K; Nieto-Oberhuber C; Cobos-Correa A; Ferretti S; Schübeler D; Galli GG
Nat Commun; 2021 Apr; 12(1):2442. PubMed ID: 33903593
[TBL] [Abstract] [Full Text] [Related]
8. [Clinicopathological Features of Intrathyroid Thymic Carcinoma].
Zheng ZG; Sun WY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Feb; 43(1):42-46. PubMed ID: 33663661
[TBL] [Abstract] [Full Text] [Related]
9. Identification of an immune-related key gene, PPARGC1A, in the development of anaplastic thyroid carcinoma: in-silico study and in-vitro evaluation.
Huang Y; Ling J; Chang A; Ye H; Zhao H; Zhuo X
Minerva Endocrinol (Torino); 2022 Jun; 47(2):150-159. PubMed ID: 32720497
[TBL] [Abstract] [Full Text] [Related]
10. Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study.
Bardet S; Goardon N; Lequesne J; Vaur D; Ciappuccini R; Leconte A; Monpeyssen H; Saguet-Rysanek V; Clarisse B; Lasne-Cardon A; Ménégaux F; Leenhardt L; Buffet C
Endocrine; 2021 Feb; 71(2):407-417. PubMed ID: 32638211
[TBL] [Abstract] [Full Text] [Related]
11. Signet ring cell variant of follicular thyroid carcinoma: Report of two cases with focus on morphological, expressional and genetic characteristics.
Hysek M; Jatta K; Stenman A; Darai-Ramqvist E; Zedenius J; Höög A; Juhlin CC
Diagn Pathol; 2019 Nov; 14(1):127. PubMed ID: 31699114
[TBL] [Abstract] [Full Text] [Related]
12. Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other cancers.
Jetten AM
Trends Cancer; 2019 Sep; 5(9):547-557. PubMed ID: 31474360
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate thyroid Nodules.
Goldner WS; Angell TE; McAdoo SL; Babiarz J; Sadow PM; Nabhan FA; Nasr C; Kloos RT
Thyroid; 2019 Nov; 29(11):1594-1605. PubMed ID: 31469053
[No Abstract] [Full Text] [Related]
14. Coding Molecular Determinants of thyroid cancer Development and Progression.
Valvo V; Nucera C
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):37-59. PubMed ID: 30717910
[TBL] [Abstract] [Full Text] [Related]
15. Metastasis to Stomach in a Patient with Anaplastic thyroid Carcinoma: A Clinical Challenge.
Fuladi R; Nagarkar R; Roy S
Am J Case Rep; 2019 Feb; 20():134-138. PubMed ID: 30705249
[TBL] [Abstract] [Full Text] [Related]
16. Mammary Analogue Secretory Carcinoma of the thyroid Mimicking Locally Advanced Papillary thyroid Carcinoma: A Rare Case Report.
Liao H; Khan A; Miron PM; Cornejo KM
Int J Surg Pathol; 2018 Aug; 26(5):459-463. PubMed ID: 29228842
[TBL] [Abstract] [Full Text] [Related]
17. Molecular pathology and thyroid FNA.
Poller DN; Glaysher S
Cytopathology; 2017 Dec; 28(6):475-481. PubMed ID: 29165888
[TBL] [Abstract] [Full Text] [Related]
18. Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer.
Song YS; Lim JA; Min HS; Kim MJ; Choi HS; Cho SW; Moon JH; Yi KH; Park DJ; Cho BY; Park YJ
Eur J Endocrinol; 2017 Dec; 177(6):465-473. PubMed ID: 28864536
[TBL] [Abstract] [Full Text] [Related]
19. Chromophobe renal cell carcinoma-like thyroid carcinoma: A novel clinicopathologic entity possibly associated with tuberous sclerosis complex.
Hirokawa M; Miyauchi A; Kihara M; Kudo T; Hashimoto Y; Suzuki S; Daa T; Vuong HG; Mitsutake N
Endocr J; 2017 Sep; 64(9):843-850. PubMed ID: 28680002
[TBL] [Abstract] [Full Text] [Related]
20. Molecular Markers Involved in Tumorigenesis of thyroid Carcinoma: Focus on Aggressive Histotypes.
Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
[TBL] [Abstract] [Full Text] [Related]
[Next]
